As a result, healthy carriers of CHEK2 pathogenic mutations were offered breast and colorectal cancer surveillance in accordance with NCCN and AIOM (Italian Association of Medical Oncology) while also taking their family history into account. Here, CHEK2 is linked to colorectal cancer.